BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) — Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences:
- UBS Global Healthcare Conference in New York on Monday, May 23 at 9:15 a.m. EDT. CEO Matt Gline will present.
- HC Wainwright Global Investment Conference in Miami on Tuesday, May 24 at 8:30 a.m. EDT. Chief Financial Officer Richard Pulik will participate in a fireside chat.
- Jefferies Healthcare Conference in New York on Wednesday, June 8 at 2 p.m. EDT. CEO Matt Gline will participate in a fireside chat.
- Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14 at 8:40 a.m. PDT / 11:40 a.m. EDT. Chief Financial Officer Richard Pulik and Chairman and Chief Investment Officer Mayukh Sukhatme will join in a fireside chat.
A live webcast of each presentation and fireside chat will be available under “Events and Presentations” in the Investors section of Roivant’s website at https://investor.roivant.com/news-events/events, and archived recordings will be available after each presentation.
About Roivant Sciences
Roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by creatively building technologies and developing talent, leveraging the Roivant platform to launch “Vants”, agile and focused biopharmaceutical and health technology companies. For more information, visit www.roivant.com.
Roivant Sciences Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act. of 1934, as amended (the “Exchange Act”), which are generally identified by the use of words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “will expect”, “intend”, “may”, “could”, “plan”, “possible”, “potential”, “predict”, “plan”, “should”, “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of such words does not mean that a statement is not forward-looking. We intend that these forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of key results from our ongoing clinical trials, and any commercial potential of our product candidates. In addition, any statement that refers to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, is a forward-looking statement.
Although we believe that our plans, intentions, expectations and strategies as reflected or implied by these forward-looking statements are reasonable, we cannot guarantee that the plans, intentions, expectations or strategies will be achieved or achieved. In addition, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, the risks set forth in the section Risk factors from our filings with the United States Securities and Exchange Commission. In addition, we operate in a highly competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based on the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . . Except as required by applicable law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Roivant Investor Relations